ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Exclusion Criteria

• •Age \< 40 years.
• •ACS event occurring more than 52 weeks prior to randomization visit.
• •LDL-C likely to be \<70 mg/dL (\<1.81 mmo/L), and apolipoprotein B (ApoB) \<80 mg/dL (\<0.8 g/L), and non - high-density lipoprotein cholesterol (HDL-C) \<100 mg/dL (\<2.59 mmol/L) with evidence-based medical and dietary management of dyslipidemia.
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.